Skip to content
Bomb Report – Lifestyle
Author:
Currus Biologics
Octane Biotech and Currus Biologics Automate Manufacturing of CUR-001 CAR T-Cell Therapy on the Cocoon® Platform
October 26, 2026
Currus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours
September 28, 2026